First human trial of the adenovirus type-5 vectored COVID-19 vaccine
The first human trial for CanSino’s non-replicating recombinant adenovirus type-5 vectored COVID-19 vaccine was tested on healthy adults in Wuhan, Hubei Province, China. The study assessed the safety, tolerability, and immunogenicity of the COVID-19 vaccine 28 days post-vaccination.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Learn After
Methods for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Results for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Discussion on Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial